Neurophysiological Markers in the Depressive Episode Characterized by Anhedonic Drug Resistance: Evaluation of Motor Skills and P300 Wave
NCT ID: NCT04456868
Last Updated: 2020-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
65 participants
INTERVENTIONAL
2020-07-24
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
Electroencephalogram
Electroencephalogram will be done for P300 wave assessment
walking test
8-Meter walking test will be done for gait parameter assessment
Quality of life questionnaire
Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Anhedonic drug-resistant bipolar depression patient
Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
Electroencephalogram
Electroencephalogram will be done for P300 wave assessment
walking test
8-Meter walking test will be done for gait parameter assessment
Quality of life questionnaire
Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Position emission tomography
Position emission tomography will be done for
Non-anhedonic drug-resistant bipolar depression Pat
Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
Electroencephalogram
Electroencephalogram will be done for P300 wave assessment
walking test
8-Meter walking test will be done for gait parameter assessment
Quality of life questionnaire
Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Position emission tomography
Position emission tomography will be done for
Mild to moderate Parkinson's disease patient
Adult patients at least 18 years of age with mild to moderate Parkinson's disease
Electroencephalogram
Electroencephalogram will be done for P300 wave assessment
walking test
8-Meter walking test will be done for gait parameter assessment
Quality of life questionnaire
Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Position emission tomography
Position emission tomography will be done for
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electroencephalogram
Electroencephalogram will be done for P300 wave assessment
walking test
8-Meter walking test will be done for gait parameter assessment
Quality of life questionnaire
Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
Position emission tomography
Position emission tomography will be done for
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person who is ≥ 18 years old and ≤ 70 years old
* Subject without neurological history
* Subject without psychiatric history in the semi-structured interview Mini International Neuropsychiatric Interview (MINI).
* Subject having read and understood the newsletter and signed the consent form
* Subject affiliated to a social security scheme.
* Subject capable of understanding spoken and written French.
* Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal.
Patients with drug-resistant bipolar anhedonic depression:
* Patient whose age is ≥ 18 years and ≤ 70 years.
* Patient with depression meeting DSM-5 criteria (Appendix 4) evolving in the context of bipolar disorder.
* Patient with a resistance level greater than or equal to 1 according to the Pacchiarotti classification.
* Patient with an SHAPS anhedonia score greater than 5/14.
* Patient with no other psychiatric pathology in the semi-structured interview Mini International Neuropsychiatric Interview (MINI).
* Stable lithium treatment in the 7 days preceding the inclusion visit.
* Patient who has not received treatment with electroconvulsive therapy in the 2 months preceding the inclusion visit.
* Patient having a normal neurological examination.
* Patient who has read and understood the information letter and signed the consent form.
* Patient affiliated to a social security scheme.
* Patient able to understand spoken and written French.
* Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal.Patient dont l'âge est ≥ 18 ans et ≤ 70 ans.
Patients with drug-resistant bipolar depression of the non-anhedonic type:
* Patient whose age is ≥ 18 years and ≤ 70 years.
* Presence of a depression meeting the criteria of DSM-5 (Annex 4) evolving in the context of bipolar disorder.
* Patient with a resistance level greater than or equal to 1 according to the Pacchiarotti classification.
* Patient with SHAPS anhedonia score less than or equal to 3/14.
* Absence of another psychiatric pathology in the semi-structured interview Mini International Neuropsychiatric Interview (MINI).
* Stable lithium treatment in the 7 days preceding the inclusion visit.
* Patient who has not received treatment with electroconvulsive therapy in the 2 months preceding the inclusion visit.
* Patient having a normal neurological examination.
* Patient who has read and understood the information letter and signed the consent form.
* Patient affiliated to a social security scheme.
* Patient able to understand spoken and written French.
* Woman of reproductive age with effective contraception as defined by the WHO, for at least three months.
Patients with Parkinson's disease :
* Patient whose age is ≥ 18 years and ≤ 70 years.
* Patient with idiopathic Parkinson's disease as defined by the diagnostic criteria of the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) (Annex 8).
* Patient with Parkinson's disease stage less than 3 (mild or moderate severity) according to the classification of Hoehn \& Yahr (Annex 7).
* Patient treated with L-DOPA associated with a dopa-decarboxylase inhibitor (DDC) and who has not changed antiparkinsonian treatment for at least 1 month before the inclusion visit.
* Patient with no neurological disorders other than those induced by Parkinson's disease.
* Patient without depression defined by a score less than or equal to 8 on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Annex 10).
* Patient with no psychiatric pathology at the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9).
* Patient who has read and understood the information letter and signed the consent form.
* Patient affiliated to a social security scheme.
* Patient able to understand spoken and written French.
* Woman of childbearing age with effective contraception as defined by the WHO, for at least three months.
Exclusion Criteria
* Person with a psychiatric disorder in the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9).
* Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship.
* Subjects with poor understanding of spoken or written French
* Existence of a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters.
* Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding.
* Taking unauthorized treatment during the study and:
* In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT).
* In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics.
* In the 2 months preceding inclusion for electroconvulsive therapy
* In the 6 months prior to inclusion for antipsychotics.
* Dependence on a substance other than nicotine.
Patients with drug-resistant bipolar anhedonic depression:
* Patient with depression with psychotic characteristics.
* Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship.
* Subjects with poor understanding of spoken or written French
* Patient with SHAPS anhedonia score less than or equal to 5/14 (Annex 2).
* Patient with a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters.
* Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding.
* Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients.
* Taking unauthorized treatment during the study and:
* In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT).
* In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics.
* In the 2 months preceding inclusion for electroconvulsive therapy
* In the 6 months prior to inclusion for antipsychotics.
* Dependence on a substance other than nicotine.
Patients with drug-resistant bipolar depression of the non-anhedonic type:
* Pa Patient with depression with psychotic characteristics.
* Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship.
* Subjects with poor understanding of spoken or written French
* Patient with SHAPS anhedonia score less than or equal to 5/14 (Annex 2).
* Patient with a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters.
* Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding.
* Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients.
* Taking unauthorized treatment during the study and:
* In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT).
* In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics.
* In the 2 months preceding inclusion for electroconvulsive therapy
* In the 6 months prior to inclusion for antipsychotics.
* Dependence on a substance other than nicotine.
Patients with Parkinson's disease:
* Patient with depression.
* Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship.
* Subjects with poor understanding of spoken or written French
* Severe form of Parkinson's disease with a Hoehn and Yhar upper or equal 4 (Annex 7).
* Patient with other neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters.
* Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding.
* Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients.
* Taking unauthorized treatment during the study and:
* In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT).
* In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics.
* In the 2 months preceding inclusion for electroconvulsive therapy
* In the 6 months prior to inclusion for antipsychotics.
* Dependence on a substance other than nicotine.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Laure WELTER, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rouen University Hospital
Rouen, , France
CHSR du Rouvray
Saint-Étienne-du-Rouvray, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marie-Laure WELTER, Pr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018/0426/HP
Identifier Type: -
Identifier Source: org_study_id